- CA$120.45m
- CA$105.54m
- CA$35.03m
- 89
- 50
- 76
- 84
Annual cashflow statement for Biosyent, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 3.8 | 6.28 | 5.46 | 6.46 | 7.27 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 0.122 | 0.18 | 0.141 | -0.276 | 0.044 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 2.49 | -2.18 | -1.09 | -1.45 | 0.888 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | 6.89 | 4.67 | 4.95 | 5.05 | 8.66 |
| Capital Expenditures | -0.014 | -0.085 | -0.047 | -0.06 | -0.042 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 3.4 | -4.75 | -10.7 | 0.943 | 3.33 |
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Change in Net Intangibles | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 3.39 | -4.84 | -10.8 | 0.884 | 3.29 |
| Financing Cash Flow Items | — | — | — | -0.443 | -0.639 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -3.37 | -2.08 | -4.37 | -5.78 | -7.83 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 6.85 | -2.26 | -10.2 | 0.12 | 4.13 |